Try our mobile app

Switch to company model in classical logic    *

General information

Country: NETHERLANDS

Sector: Biotechnology

uniQure N.V. delivers gene therapy with single treatments for curative results. The Company develops a modular platform to bring new disease modifying therapies to patients with severe genetic diseases, as well as offers ongoing clinical programs in hemophilia B and pre-clinical proof-of-concept in Huntington"s disease.
Website: uniqure.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 56.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 864.2%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.12 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -83.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 87.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -10.9x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.3 mln (-0.114% of cap.)

Key Financials (Download financials)

Ticker: QURE
Share price, USD:  (-0.8%)4.67
year average price 9.32  


year start price 19.78 2023-04-22

max close price 22.20 2023-05-10

min close price 4.67 2024-04-17

current price 4.67 2024-04-20
Common stocks: 46 772 430

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  56.9%
Historical growth of EBITDA:  33.3%
EV / Sales: -0.1x
Margin (EBITDA LTM / Revenue): -1 864.2%
Fundamental value created in LTM:
Market Cap ($m): 218
Net Debt ($m): -389
EV (Enterprise Value): -171
Price to Book: 1.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-02-28Zacks Investment Research

UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates

2023-11-07Zacks Investment Research

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

2023-10-06Zacks Investment Research

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

2023-10-05The Motley Fool

Why Shares of uniQure Are Up Thursday

2023-10-05Proactive Investors

uniQure slashes more than half of its research programs to preserve cash

2023-10-05Market Watch

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

2023-09-05The Motley Fool

Why Shares of uniQure Are Dropping Tuesday

2023-08-01Zacks Investment Research

UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

2023-06-22The Motley Fool

Why uniQure Stock Cratered This Week

2023-06-22Zacks Investment Research

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol QURE QURE QURE QURE QURE QURE
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-28 2023-11-07 2023-08-01 2023-05-09 2023-02-27 2022-11-02
acceptedDate 2024-02-28 07:51:22 2023-11-07 07:52:53 2023-08-01 07:37:29 2023-05-09 07:20:43 2023-02-27 07:20:08 2022-11-02 07:45:41
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 7M 1M 2M 5M 103M 1M
costOfRevenue 9M 1M 1M 2M 2M 861 000
grossProfit -2M 401 000 1M 3M 101M 588 000
grossProfitRatio -0.321 0.285 0.442 0.543 0.984 0.406
researchAndDevelopmentExpenses 43M 65M 46M 61M 58M 48M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 17M 18M 21M 18M 18M 13M
otherExpenses -895 000 -8M -127 000 -2M -2M -1M
operatingExpenses 60M 82M 66M 77M 75M 60M
costAndExpenses 68M 83M 67M 79M 76M 61M
interestIncome 7M 7M 3M 2M 492 000 39 000
interestExpense 16M -15M 7M 4M 3M 3M
depreciationAndAmortization 4M 3M 3M 4M 2M 2M
ebitda -50M -82M -59M -70M 29M -57M
ebitdaratio -7.533 -58.193 -24.466 -13.141 0.279 -39.597
operatingIncome -62M -82M -65M -74M 27M -60M
operatingIncomeRatio -9.231 -58.193 -26.868 -13.929 0.258 -41.075
totalOtherIncomeExpensesNet 118 000 -8M 374 000 -4M -20M 11M
incomeBeforeTax -70M -90M -68M -78M 7M -48M
incomeBeforeTaxRatio -10.491 -63.710 -28.204 -14.729 0.064 -33.255
incomeTaxExpense 3M -69 000 163 000 -1M -207 000 -329 000
netIncome -73M -90M -68M -77M 7M -48M
netIncomeRatio -10.944 -63.661 -28.272 -14.503 0.066 -33.028
eps -1.530 -1.880 -1.440 -1.630 0.150 -1.020
epsdiluted -1.530 -1.880 -1.440 -1.630 0.150 -1.020
weightedAverageShsOut 48M 48M 48M 47M 47M 47M
weightedAverageShsOutDil 48M 48M 48M 47M 47M 47M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol QURE QURE QURE QURE QURE QURE
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-28 2023-11-07 2023-08-01 2023-05-09 2023-02-27 2022-11-02
acceptedDate 2024-02-28 07:51:22 2023-11-07 07:52:53 2023-08-01 07:37:29 2023-05-09 07:20:43 2023-02-27 07:20:08 2022-11-02 07:45:41
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 241M 229M 514M 154M 228M 440M
shortTermInvestments 377M 429M 115M 161M 125M 0
cashAndShortTermInvestments 618M 659M 629M 315M 353M 440M
netReceivables 4M 2M 103M 105M 102M 4M
inventory 12M 16M 10M 7M 7M 4M
otherCurrentAssets 3M 3M 3M 2M 3M 3M
totalCurrentAssets 652M 694M 757M 443M 477M 465M
propertyPlantEquipmentNet 75M 76M 80M 82M 83M 76M
goodwill 26M 25M 26M 26M 26M 23M
intangibleAssets 60M 58M 60M 60M 59M 54M
goodwillAndIntangibleAssets 87M 83M 86M 86M 84M 77M
longTermInvestments 0 0 0 0 40M 0
taxAssets 12M 12M 14M 14M 15M 15M
otherNonCurrentAssets 5M 6M 6M 6M 6M 6M
totalNonCurrentAssets 180M 178M 186M 188M 228M 174M
otherAssets 0 0 0 0 0 0
totalAssets 832M 872M 943M 631M 705M 638M
accountPayables 7M 6M 9M 9M 11M 8M
shortTermDebt 8M 8M 8M 8M 8M 6M
taxPayables 0 0 0 0 0 0
deferredRevenue 29M 28M 24M 0 0 0
otherCurrentLiabilities 30M 27M 28M 50M 57M 50M
totalCurrentLiabilities 74M 69M 68M 66M 76M 64M
longTermDebt 130M 130M 131M 134M 135M 132M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 8M 5M 7M 7M 8M 9M
otherNonCurrentLiabilities 413M 399M 383M 11M 10M 139M
totalNonCurrentLiabilities 550M 534M 521M 152M 153M 153M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 37M 37M 38M 39M 40M 36M
totalLiabilities 624M 603M 589M 218M 229M 217M
preferredStock 0 0 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M
retainedEarnings -890M -817M -728M -659M -582M -589M
accumulatedOtherComprehensiveIncomeLoss -54M -59M -52M -52M -58M -93M
othertotalStockholdersEquity 1 149M 1 142M 1 131M 1 122M 1 113M 1 100M
totalStockholdersEquity 208M 269M 353M 413M 476M 421M
totalEquity 208M 269M 353M 413M 476M 421M
totalLiabilitiesAndStockholdersEquity 832M 872M 943M 631M 705M 638M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 832M 872M 943M 631M 705M 638M
totalInvestments 377M 429M 115M 161M 165M 0
totalDebt 138M 138M 139M 142M 143M 139M
netDebt -103M -91M -375M -12M -85M -302M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol QURE QURE QURE QURE QURE QURE
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-28 2023-11-07 2023-08-01 2023-05-09 2023-02-27 2022-11-02
acceptedDate 2024-02-28 07:51:22 2023-11-07 07:52:53 2023-08-01 07:37:29 2023-05-09 07:20:43 2023-02-27 07:20:08 2022-11-02 07:45:41
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -73M -90M -68M -77M 7M -48M
depreciationAndAmortization 4M 3M 3M 3M 2M 2M
deferredIncomeTax 3M -69 000 163 000 -1M -207 000 -329 000
stockBasedCompensation 7M 11M 9M 8M 12M 8M
changeInWorkingCapital 4M 92M -3M -12M -89M -4M
accountsReceivables -98M 96M 2M -936 000 -46M -5M
inventory 2M -5M -3M -553 000 -3M -1M
accountsPayables 615 000 -4M 449 000 -2M 5M -3M
otherWorkingCapital 99M 5M -2M -9M -45M 5M
otherNonCashItems 5M 23M 3M 2M 14M -7M
netCashProvidedByOperatingActivities -50M 39M -57M -78M -55M -49M
investmentsInPropertyPlantAndEquipment -2M -2M -1M -2M -5M -4M
acquisitionsNet 0 369M 0 0 2M -1M
purchasesOfInvestments 4M -369M 0 0 0 0
salesMaturitiesOfInvestments 62M 54M 47M 5M 0 0
otherInvestingActivites -4M -366M 0 0 -165M 0
netCashUsedForInvestingActivites 60M -314M 46M 3M -168M -5M
debtRepayment -4M -166 467 -373M 0 0 0
commonStockIssued 46 000 56 000 75 000 131 000 1M -543 000
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 4M -7M 743M 0 -844 000 844 000
netCashUsedProvidedByFinancingActivities 46 000 -8M 370M 131 000 601 000 301 000
effectOfForexChangesOnCash 2M -1M 778 000 1M 10M -6M
netChangeInCash 12M -284M 360M -74M -212M -60M
cashAtEndOfPeriod 245M 233M 517M 157M 231M 443M
cashAtBeginningOfPeriod 233M 517M 157M 231M 443M 504M
operatingCashFlow -50M 39M -57M -78M -55M -49M
capitalExpenditure -2M -2M -1M -2M -5M -4M
freeCashFlow -52M 37M -58M -81M -60M -53M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-28 12:05 ET
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
2023-12-19 12:05 ET
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
2023-12-12 00:30 ET
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
2023-12-08 12:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 12:05 ET
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
2023-11-07 12:05 ET
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-10-27 14:00 ET
CSL and uniQure Win 2023 Prix Galien USA Award
2023-10-24 11:05 ET
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
2023-10-05 11:05 ET
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
2023-10-02 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-05 11:05 ET
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
2023-08-01 11:05 ET
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-06-26 11:11 ET
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
2023-06-21 11:05 ET
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
2023-06-20 11:05 ET
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
2023-06-20 11:00 ET
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
2023-06-16 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-15 11:05 ET
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
2023-05-09 11:05 ET
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-05-02 20:40 ET
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
2023-05-02 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-13 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-02 12:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in March
2023-02-27 12:05 ET
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
2023-02-23 13:05 ET
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
2023-02-23 13:00 ET
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
2023-02-21 12:05 ET
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
2023-01-31 12:05 ET
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
2022-12-20 12:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-16 12:15 ET
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
2022-12-10 15:00 ET
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
2022-11-29 16:00 ET
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
2022-11-22 21:40 ET
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
2022-11-22 20:59 ET
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
2022-11-17 12:05 ET
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
2022-11-02 11:05 ET
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
2022-10-11 11:05 ET
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
2022-10-03 11:05 ET
uniQure to Participate in Upcoming Industry Conferences in October
2022-09-06 11:05 ET
uniQure to Participate in Upcoming Industry Conferences in September
2022-08-08 11:05 ET
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
2022-06-23 11:05 ET
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
2022-06-22 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-24 12:00 ET
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
2022-05-11 11:05 ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-02 20:45 ET
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
2022-05-02 11:05 ET
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
2022-03-28 06:13 ET
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
2022-03-21 11:05 ET
uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2022-02-25 12:05 ET
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
2022-02-07 12:05 ET
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
2022-02-04 15:20 ET
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
2021-12-16 12:00 ET
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
2021-12-15 12:33 ET
CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
2021-12-09 12:05 ET
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
2021-11-02 11:05 ET
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-11-01 11:05 ET
uniQure to Participate in Upcoming Industry Conferences in November
2021-10-25 11:05 ET
uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
2021-10-21 13:30 ET
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
2021-10-19 11:05 ET
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
2021-09-30 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in October
2021-09-07 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in September
2021-08-30 11:05 ET
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-07-26 11:05 ET
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
2021-07-02 13:00 ET
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
2021-06-22 15:31 ET
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
2021-06-22 15:31 ET
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
2021-06-16 11:05 ET
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-06-02 11:34 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in June
2021-05-27 11:05 ET
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-05-13 11:00 ET
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
2021-05-10 11:05 ET
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
2021-05-06 11:05 ET
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
2021-05-06 11:00 ET
uniQure announces closing of commercialization and license agreement with CSL Behring
2021-05-03 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in May
2021-04-28 11:05 ET
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
2021-04-26 11:05 ET
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
2021-04-08 11:05 ET
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
2021-04-05 11:05 ET
uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-04-01 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in April
2021-03-29 11:05 ET
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
2021-03-01 12:05 ET
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
2021-02-26 12:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in March
2021-02-08 12:05 ET
uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2021-02-01 12:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in February
2020-12-21 12:05 ET
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
2020-12-08 12:00 ET
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
2020-12-07 21:05 ET
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
2020-12-02 12:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in December
2020-11-30 12:05 ET
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
2020-11-19 14:10 ET
uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
2020-11-04 15:46 ET
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
2020-11-04 12:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in November
2020-10-27 11:05 ET
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
2020-10-13 11:05 ET
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2020-09-30 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in October
2020-09-25 11:05 ET
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
2020-09-03 11:05 ET
uniQure to Participate in Multiple Upcoming Industry Conferences in September
2020-08-26 11:05 ET
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
2020-07-30 11:05 ET
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
2019-06-17 13:31 ET
Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure?

SEC forms

Show financial reports only

SEC form 8
2024-02-28 08:00 ET
UniQure published news for 2023 q4
SEC form 8
2024-02-28 08:00 ET
UniQure reported for 2023 q4
SEC form 10
2024-02-28 07:51 ET
UniQure reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
UniQure reported for 2023 q4
SEC form 10
2023-11-07 07:52 ET
UniQure reported for 2023 q3
SEC form 8
2023-11-07 07:31 ET
UniQure reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
UniQure reported for 2023 q3
SEC form 6
2023-08-01 16:30 ET
UniQure published news for 2023 q2
SEC form 10
2023-08-01 07:37 ET
UniQure reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
UniQure reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
UniQure published news for 2023 q2
SEC form 6
2023-06-22 16:59 ET
UniQure published news for 2023 q1
SEC form 6
2023-06-16 16:30 ET
UniQure published news for 2023 q1
SEC form 6
2023-06-15 20:00 ET
UniQure published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
UniQure published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
UniQure reported for 2023 q1
SEC form 6
2023-04-05 16:30 ET
UniQure published news for 2023 q1
SEC form 6
2023-02-27 17:27 ET
UniQure published news for 2022 q4
SEC form 10
2023-02-27 07:20 ET
UniQure reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
UniQure published news for 2022 q4
SEC form 10
2023-02-27 00:00 ET
UniQure reported for 2022 q4
SEC form 6
2023-02-21 16:20 ET
UniQure published news for 2022 q4
SEC form 6
2023-01-31 16:15 ET
UniQure published news for 2022 q4
SEC form 6
2022-12-16 16:15 ET
UniQure published news for 2022 q3
SEC form 6
2022-11-28 16:47 ET
UniQure published news for 2022 q3
SEC form 6
2022-11-23 09:07 ET
UniQure published news for 2022 q3
SEC form 6
2022-11-02 16:15 ET
UniQure reported for 2022 q3
SEC form 10
2022-11-02 07:45 ET
UniQure reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
UniQure reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
UniQure reported for 2022 q3
SEC form 6
2022-08-08 09:00 ET
UniQure reported for 2022 q2
SEC form 10
2022-08-08 08:00 ET
UniQure reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
UniQure reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
UniQure reported for 2022 q2
SEC form 6
2022-06-15 16:30 ET
UniQure published news for 2022 q1
SEC form 6
2022-05-24 16:45 ET
UniQure published news for 2022 q1
SEC form 6
2022-05-02 16:30 ET
UniQure published news for 2022 q1
SEC form 10
2022-05-02 07:31 ET
UniQure reported for 2022 q1
SEC form 8
2022-05-02 00:00 ET
UniQure published news for 2022 q1
SEC form 10
2022-05-02 00:00 ET
UniQure reported for 2022 q1
SEC form 6
2022-04-29 16:15 ET
UniQure published news for 2022 q1
SEC form 6
2022-04-19 16:43 ET
UniQure published news for 2022 q1
SEC form 6
2022-03-22 16:15 ET
UniQure published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
UniQure published news for 2021 q4
SEC form 6
2022-02-25 18:33 ET
UniQure published news for 2021 q4
SEC form 10
2022-02-25 07:36 ET
UniQure published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
UniQure published news for 2021 q4
SEC form 6
2022-02-08 16:15 ET
UniQure published news for 2021 q4
SEC form 6
2022-02-04 16:15 ET
UniQure published news for 2021 q4
SEC form 6
2021-12-28 16:15 ET
UniQure published news for 2021 q3
SEC form 6
2021-12-17 16:15 ET
UniQure published news for 2021 q3
SEC form 6
2021-12-13 16:16 ET
UniQure published news for 2021 q3
SEC form 6
2021-10-25 16:16 ET
UniQure published news for 2021 q3
SEC form 10
2021-10-25 07:40 ET
UniQure published news for 2021 q3
SEC form 10
2021-10-25 00:00 ET
UniQure published news for 2021 q3
SEC form 8
2021-10-25 00:00 ET
UniQure published news for 2021 q3
SEC form 6
2021-10-22 20:03 ET
UniQure published news for 2021 q3
SEC form 6
2021-10-21 16:15 ET
UniQure published news for 2021 q3
SEC form 6
2021-09-17 16:31 ET
UniQure published news for 2021 q2
SEC form 6
2021-07-30 16:05 ET
UniQure published news for 2021 q2
SEC form 6
2021-07-27 07:44 ET
UniQure published news for 2021 q2
SEC form 8
2021-07-27 00:00 ET
UniQure published news for 2021 q2
SEC form 10
2021-07-26 16:04 ET
UniQure published news for 2021 q2
SEC form 10
2021-07-26 00:00 ET
UniQure published news for 2021 q2
SEC form 6
2021-06-23 06:03 ET
UniQure published news for 2021 q1
SEC form 6
2021-06-21 16:07 ET
UniQure published news for 2021 q1
SEC form 6
2021-06-17 09:49 ET
UniQure published news for 2021 q1
SEC form 6
2021-05-21 17:25 ET
UniQure published news for 2021 q1
SEC form 6
2021-05-10 17:25 ET
UniQure published news for 2021 q1
SEC form 10
2021-05-10 08:53 ET
UniQure published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
UniQure published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
UniQure published news for 2021 q1
SEC form 6
2021-05-07 17:11 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-30 17:20 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-26 16:34 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-22 16:31 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-20 16:39 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-05 17:25 ET
UniQure published news for 2021 q1
SEC form 6
2021-04-01 09:05 ET
UniQure published news for 2021 q1
SEC form 6
2021-03-01 19:32 ET
UniQure published news for 2020 q4
SEC form 10
2021-03-01 16:51 ET
UniQure published news for 2020 q4
SEC form 6
2021-03-01 07:39 ET
UniQure published news for 2020 q4
SEC form 6
2021-02-09 16:31 ET
UniQure published news for 2020 q4
SEC form 6
2021-02-02 06:01 ET
UniQure published news for 2020 q4
SEC form 6
2021-01-07 17:11 ET
UniQure published news for 2020 q4
SEC form 6
2020-12-21 08:00 ET
UniQure published news for 2020 q3
SEC form 6
2020-12-09 16:15 ET
UniQure published news for 2020 q3
SEC form 6
2020-12-07 17:25 ET
UniQure published news for 2020 q3
SEC form 6
2020-11-19 09:15 ET
UniQure published news for 2020 q3
SEC form 6
2020-11-02 16:28 ET
UniQure published news for 2020 q3
SEC form 6
2020-10-28 16:15 ET
UniQure published news for 2020 q3
SEC form 10
2020-10-27 17:19 ET
UniQure published news for 2020 q3